Paper8097101
Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.
Sheldon P and 1 other. Br J Clin Pharmacol, 1993. Cited by 7 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen. Papers, record 8097101. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8097101
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminosalicylic Acids | Major topic |
| Antibody Formation | Major topic |
| Cholera Toxin | Major topic |
| Sulfapyridine | Major topic |
| Sulfasalazine | Major topic |
| Administration, Oral | |
| Animals | |
| Female | |
| Immunoglobulin A | |
| Immunoglobulin G | |
| Immunoglobulin M | |
| Injections, Subcutaneous | |
| Mice | |
| Mice, Inbred C57BL |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 72239 | An experiment to determine the active therapeutic moiety of sulphasalazine. | Lancet | 1977 | https://conductscience.org/library/papers/72239 | PubMed |
| 2 | 6121162 | Mode of action of sulphasalazine: an alternative view. | Lancet | 1982 | https://conductscience.org/library/papers/6121162 | PubMed |
| 3 | 6131674 | Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. | Biochem Pharmacol | 1983 | https://conductscience.org/library/papers/6131674 | PubMed |
| 4 | 6407598 | Effect of magnesium on blood pressure. | Br Med J (Clin Res Ed) | 1983 | https://conductscience.org/library/papers/6407598 | PubMed |
| 5 | 6746103 | Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. | Int Arch Allergy Appl Immunol | 1984 | https://conductscience.org/library/papers/6746103 | PubMed |
| 6 | 6151882 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. | Clin Rheumatol | 1984 | https://conductscience.org/library/papers/6151882 | PubMed |
| 7 | 1360861 | Effect of sulphasalazine on antibody response to oral antigen. | Br J Rheumatol | 1992 | https://conductscience.org/library/papers/1360861 | PubMed |
| 8 | 2872187 | Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. | Immunopharmacology | 1986 | https://conductscience.org/library/papers/2872187 | PubMed |
| 9 | 3623690 | Role of Peyer's patch in the intestinal immune response to cholera toxin in enterically immunized rats. | Infect Immun | 1987 | https://conductscience.org/library/papers/3623690 | PubMed |
| 10 | 2899645 | Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. | J Rheumatol | 1988 | https://conductscience.org/library/papers/2899645 | PubMed |
| 11 | 2899646 | In vitro immunomodulatory effects of sulfasalazine and its metabolites. | J Rheumatol | 1988 | https://conductscience.org/library/papers/2899646 | PubMed |
| 12 | 2902897 | Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? | Br J Rheumatol | 1988 | https://conductscience.org/library/papers/2902897 | PubMed |
| 13 | 1968449 | The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells. | Immunopharmacology | 1990 | https://conductscience.org/library/papers/1968449 | PubMed |
| 14 | 2860942 | Which component of sulphasalazine is active in rheumatoid arthritis? | Br Med J (Clin Res Ed) | 1985 | https://conductscience.org/library/papers/2860942 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 7763101 | Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis. | Ann Rheum Dis | 1995 | https://conductscience.org/library/papers/7763101 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8097101
GET https://conductscience.org/api/papers/v1/8097101/authors